Little Green Pharma Pivots to Europe as Australian Cannabis Exports Accelerate

Export Strategy Shifts Toward European Medical Programs

Little Green Pharma is prioritizing European distribution channels as demand for Australian-grown medicinal cannabis rises across the continent. The company operates cultivation facilities in Western Australia. It's been expanding its export footprint since securing Good Manufacturing Practice (GMP) certification—a prerequisite for entering most European Union markets.

Australia's Therapeutic Goods Administration (TGA) has approved dozens of medicinal cannabis products for export under the country's controlled-substance framework. Little Green Pharma holds export permits under the federal Office of Drug Control (ODC) licensing regime, which governs international shipments of cannabis flower, oils, and extracts.

Australia's Export Pipeline Gains Scale

Australian cannabis exports have grown significantly since 2020, with Europe accounting for the majority of shipment destinations. Producers here benefit from year-round cultivation conditions, established pharmaceutical supply chains, and regulatory frameworks that align with European import standards.

Germany, the United Kingdom, and Poland are the three largest destination markets for Australian medicinal cannabis. Germany alone imported over 15 metric tons of cannabis flower in 2025, with Australian suppliers capturing an estimated 18% share of that volume, according to data from the German Federal Institute for Drugs and Medical Devices (BfArM).

Little Green Pharma's Operational Footprint

The company operates two licensed cultivation sites in Western Australia, producing both THC-dominant and CBD-dominant strains under controlled indoor environments. Little Green Pharma has invested in automated trimming and post-harvest processing infrastructure to meet European quality benchmarks, including residue testing for pesticides and heavy metals.

Its product line includes dried flower, full-spectrum oils, and isolated cannabinoid formulations. All products destined for export undergo batch testing by third-party laboratories accredited under ISO 17025 standards.

Competitive Landscape in Australian Cannabis Exports

Little Green Pharma competes with a growing cohort of Australian exporters, including Cann Group, Cannatrek, and Althea Group, all of which have secured European distribution agreements. The Australian cannabis export sector generated approximately AUD $47 million in revenue during the 2024-25 fiscal year—a 22% increase from the prior year, according to the Australian Bureau of Statistics (ABS).

European demand is driven by expanding medical cannabis programs in Germany, which legalized recreational possession in April 2024, and the UK, where National Health Service (NHS) prescriptions for cannabis-based medicines have increased 34% year-over-year.

Regulatory Tailwinds and Trade Dynamics

Australia's export framework allows licensed producers to ship medicinal cannabis to countries with compatible regulatory regimes, provided they obtain destination-country import permits. The ODC requires exporters to submit detailed shipment manifests. Those include cannabinoid profiles, batch numbers, and end-user documentation.

The European Medicines Agency (EMA) doesn't classify cannabis as a centrally authorized medicine, meaning each EU member state sets its own import and distribution rules. This fragmentation creates compliance complexity but also opens arbitrage opportunities for producers who can navigate multiple jurisdictions.

What to Watch

The next signal for Australian exporters will be Germany's revised medical cannabis reimbursement framework, expected in Q4 2026. Changes to insurance coverage could either expand or contract the addressable market for imported flower and extracts. Meanwhile, the UK's Medicines and Healthcare products Regulatory Agency (MHRA) is reviewing a proposal to reclassify certain low-THC cannabis products as over-the-counter medicines, which would bypass prescription requirements.

Little Green Pharma's ability to scale European sales will depend on its capacity to secure long-term offtake agreements with distributors and pharmacies. For full background on Australia's export strategy and regulatory environment, see the CannIntel topic hub on Australia cannabis exports.